FrancophonIA/ELRC3.0 huggingface dataset:
English: Because Zoledronic acid Teva is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Zoledronic acid Teva on geneeriline ravim, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: This is a summary of the European public assessment report (EPAR) for Zoledronic acid Teva.
Estonian: See on ravimi Zoledronic acid Teva Euroopa avaliku hindamisaruande kokkuvõte.
English: Zoledronic acid Teva can be used to prevent bone complications in adults with advanced cancer that is affecting the bone.
Estonian: Ravimit Zoledronic acid Teva kasutatakse luutüsistuste ennetamiseks patsientidel, kellel on kaugelearenenud vähk, mis kahjustab luukude.
English: The Committee recommended that Zoledronic acid Teva be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi Zoledronic acid Teva müügiloa.
English: Zoledronic acid Teva must only be used by a doctor who has experience in the use of this type of medicine given into a vein.
Estonian: Ravimit Zoledronic acid Teva tohib patsiendile manustada üksnes seda tüüpi veenisiseste ravimite kasutamises kogenud arst.
English: By preventing the breakdown of bones, Zoledronic acid Teva also helps to reduce the amount of calcium released into the blood.
Estonian: Luukoe lagunemist peatades aitab Zoledronic acid Teva vähendada verre eralduva kaltsiumi kogust.
English: Zoledronic acid Teva can also be used to treat the hypercalcaemia caused by tumours.
Estonian: Ravimit Zoledronic acid Teva tohib kasutada ka kasvajast põhjustatud hüperkaltseemia raviks.
English: Other information about Zoledronic acid Teva
Estonian: Muu teave ravimi Zoledronic acid Teva kohta
English: Zoledronic acid Teva is a medicine that contains the active substance zoledronic acid.
Estonian: Zoledronic acid Teva on ravim, mis sisaldab toimeainena soledroonhapet.
English: Zoledronic acid Teva zoledronic acid
Estonian: Zoledronic acid Teva soledroonhape
English: The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.
Estonian: Luukoe lagundamist peatades muudab ravim luud murdudele vastupidavamaks, millega saab ennetada luumurdude tekkimist luumetastaasidega vähipatsientidel.
English: When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. A lower dose is recommended for patients with bone metastases (when cancer has spread to the bone) if they have mild to moderate problems with their kidneys.
Estonian: Kui ravimit kasutatakse luutüsistuste ennetamiseks, tohib infusiooni korrata iga 3-4 nädala järel ning patsiendid peavad võtma lisaks ka kaltsiumi ja D-vitamiini.
English: Zoledronic acid Teva is a ‘generic medicine'.
Estonian: Zoledronic acid Teva on geneeriline ravim.
English: What is Zoledronic acid Teva?
Estonian: Mis on Zoledronic acid Teva?
English: The active substance in Zoledronic acid Teva, zoledronic acid, is a bisphosphonate.
Estonian: Ravimi Zoledronic acid Teva toimeaine soledroonhape on bisfosfonaat.
English: Why has Zoledronic acid Teva been approved?
Estonian: Miks Zoledronic acid Teva heaks kiideti?
English: How is Zoledronic acid Teva used?
Estonian: Kuidas ravimit Zoledronic acid Teva kasutatakse?
English: How has Zoledronic acid Teva been studied?
Estonian: Kuidas ravimit Zoledronic acid Teva uuriti?
English: How does Zoledronic acid Teva work?
Estonian: Kuidas Zoledronic acid Teva toimib?
English: It is not recommended for patients with severe kidney problems.
Estonian: Luumetastaasidega (luudesse levinud vähk) patsientidele soovitatakse väiksemaid annuseid, kui neil on neerutalitluse kerged kuni mõõdukad häired Ravimit ei soovitata raske neeruhaigusega patsientidele.
English: Route of Administration
Estonian: Manustamisviis Pakend
English: The full EPAR for Selincro can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Selincro kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The majority of these reactions were mild or moderate and of short duration.
Estonian: Enamik kõrvalnähtudest olid oma raskusastmelt kerged või mõõdukad ja lühiaegsed.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Selincro on 25 February 2013.
Estonian: Euroopa Komisjon andis Selincro müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 25. Veebruaril
English: Selincro nalmefene
Estonian: Selincro nalmefeen
English: As a guide: a bottle of wine (750 ml; 12% alcohol by volume) contains approximately 70 g alcohol and a bottle of beer (330 ml; 5% alcohol by volume) contains approximately 13 g alcohol.
Estonian: Orienteeruv teave: pudel veini (750 ml; 12 mahuprotsenti alkoholi) sisaldab umbes 70 g alkoholi ja pudel õlut (330 ml; 5 mahuprotsenti alkoholi) sisaldab umbes 13 g alkoholi.
English: Thereafter, the patient will be asked to record his or her alcohol consumption for approximately two weeks.
Estonian: Seejärel palutakse patsiendil registreerida kahe nädala vältel oma alkoholitarbimine.
English: Only one tablet can be taken on any given day and it should preferably be taken one to two hours before they are likely to start drinking.
Estonian: Ühel päeval võib võtta ainult ühe tableti ja see tuleb sisse võtta 1-2 tundi enne võimalikku alkoholitarbimise alustamist.
English: At the patient's initial visit to their doctor, the patient's overall health, alcohol dependence, and level of alcohol consumption (based on patient reporting) will be evaluated.
Estonian: Patsiendi esimesel visiidil hindab arst patsiendi üldist terviseseisundit, alkoholisõltuvust ja alkoholitarbimise taset (patsiendi subjektiivse hinnangu alusel).
English: The CHMP decided that Selincro's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Selincro kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: With regard to safety, the side effects reported in the studies did not raise any major concerns.
Estonian: Ohutuse osas leidis inimravimite komitee, et ravimi kasutamisel teatatud kõrvalnähud ei näidanud olulisi ohutusprobleeme.
English: Before starting treatment with Selincro, the patient is asked to record their level of alcohol consumption over a two week period.
Estonian: Enne ravi alustamist Selincroga palutakse patsiendil registreerida kahe nädala vältel oma alkoholitarbimine.
English: Data on the use of Selincro from standard clinical studies are available for a period of six months to one year.
Estonian: Tavapäraste kliiniliste uuringute andmed Selincro kasutamise kohta on uuringutest kestusega 6 kuud kuni 1 aasta.
English: All patients also received counselling to help them reduce their drinking and keep to their treatment.
Estonian: Kõiki patsiente ka nõustati, et aidata neil vähendada alkoholitarbimist ja järgida ravi.
English: Other information about Selincro
Estonian: Muu teave Selincro kohta
English: This is a summary of the European public assessment report (EPAR) for Selincro.
Estonian: See on ravimi Selincro Euroopa avaliku hindamisaruande kokkuvõte.
English: If the patient has started drinking without Selincro, a tablet should be taken as soon as possible.
Estonian: Kui patsient on juba alustanud alkoholi tarbimist, siis tuleb Selincro tablett sisse võtta niipea kui võimalik.
English: For more information about treatment with Selincro, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Selincroga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Treatment must also include counselling to help the patient reduce their drinking and keep to their treatment.
Estonian: Ravi peab hõlmama ka nõustamist, et aidata patsientidel vähendada alkoholitarbimist ning järgida ravi.
English: The most common side effects (seen in more than 1 patient in 10) were nausea (feeling sick), dizziness, insomnia (difficulty sleeping) and headache.
Estonian: Selincro kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on iiveldus, peapööritus, unetus (uinumisraskus) ja peavalu.
English: Daily alcohol consumption with Selincro fell from 102 g to 44 g in the first study and from 113 g to 43 g in the second.
Estonian: Ööpäevane alkoholitarbimine vähenes Selincro rühmas esimese uuringu ajal 102 g-lt 44 g-le ja teise uuringu ajal 113 g-lt 43 g-le.
English: Selincro does not prevent the intoxicating effects of alcohol.
Estonian: Selincro ei hoia ära alkoholi toksilisi toimeid.
English: It should only be used together with psychosocial support (counselling) and only in people who do not have physical withdrawal symptoms and who do not require immediate detoxification.
Estonian: Selincrot tohib kasutada ainult koos psühhosotsiaalse toetusega (nõustamisega) ja üksnes patsientidel, kellel ei esine füüsilisi võõrutusnähte ning kes ei vaja kohest alkoholimürgistuse ravi (detoksifitseerimist).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Selincro.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Selincro must not be used in people who are hypersensitive (allergic) to nalmefene or any of its other ingredients.
Estonian: Selincrot ei tohi kasutada patsiendid, kes on nalmefeeni või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The active substance in Selincro, nalmefene, attaches to certain opioid receptors in the brain.
Estonian: Selincro toimeaine nalmefeen seondub ajus teatud opioidretseptoritega.
English: Selincro is medicine that contains the active substance nalmefene.
Estonian: Selincro on ravim, mis sisaldab toimeainena nalmefeeni.
English: Opioid receptors play a role in addiction and, by attaching to them and modifying their activity, nalmefene helps reduce the urge to drink in people accustomed to large amounts of alcohol.
Estonian: Nimetatud retseptoritega seondumise ja nende aktiivsuse muutmise teel aitab nalmefeen vähendada tungi alkoholi järele inimestel, kes on harjunud tarbima suures koguses alkoholi.
English: In these patients, after six months, the number of heavy drinking days a month with Selincro fell from 23 to 10 in the first study and from 23 to 11 in the second.
Estonian: Nimetatud patsientidel vähenes rohke alkoholitarbimisega päevade arv pärast 6-kuulist ravi Selincroga esimeses uuringus 23 päevalt 10 päevale ja teises uuringus 23 päevalt 11 päevale.
English: It must not be used in patients taking opioid medicines, in patients who have a current or recent addiction to opioids, patients with acute opioid withdrawal symptoms, or in patients suspected to have used opioids recently.
Estonian: Selincrot ei tohi kasutada patsiendid, kellel esineb või on esinenud opioidsõltuvus, samuti opioidide ägedate võõrutusnähtudega patsiendid või patsiendid, kellel kahtlustatakse hiljutist opioidide kasutamist.
English: The main measures of effectiveness were the reduction in the number of heavy drinking days and the average daily alcohol consumption after six months of treatment.
Estonian: Efektiivsuse põhinäitajad pärast 6-kuulist ravi olid rohke alkoholitarbimise päevade arvu ja keskmise ööpäevas tarbitud alkoholikoguse vähenemine.
English: Why has Selincro been approved?
Estonian: Miks Selincro heaks kiideti?
English: What is Selincro?
Estonian: Mis on Selincro?
English: It must also not be used in patients with severe liver or kidney impairment or a recent history of acute alcohol withdrawal syndrome (including hallucinations, seizures (fits) and tremors).
Estonian: Selincrot ei tohi kasutada ka raske maksa- või neerupuudulikkusega patsiendid ega patsiendid, kellel on hiljuti esinenud äge alkoholi võõrutussündroom (koos hallutsinatsioonide, krampide ja värisemisega).
English: Significant improvements, usually observed within the first four weeks of treatment, were seen in patients who were already consuming more than 60 g of alcohol per day (for men) or more than 40 g of per day (for women).
Estonian: Olulist paranemist, mis enamasti avaldus juba pärast esimest nelja ravinädalat, täheldati patsientidel, kes tarbisid ööpäevas üle 60 g (mehed) või 40 g (naised) alkoholi.
English: At the next visit (after the two weeks), Selincro may be started if the patient continues to have a high level of alcohol consumption (above 60 g per day for men and 40 g per day for women).
Estonian: Järgmisel visiidil (kahe nädala pärast) võidakse alustada ravi Selincroga, kui patsiendi alkoholitarbimine on endiselt suur (üle 60 g ööpäevas meestel või üle 40 g ööpäevas naistel).
English: What is the risk associated with Selincro?
Estonian: Mis riskid Selincroga kaasnevad?
English: These improvements were better than those seen with placebo by about 2.7 to 3.7 heavy drinking days a month and about 10 to 18 g of alcohol a day.
Estonian: Platseeboga võrreldes oli rohke alkoholitarbimisega päevade arv kuus 2,7-3,7 päeva võrra väiksem ja ööpäevas tarbiti alkoholi 10-18 g võrra vähem.
English: The CHMP noted that Selincro was shown to be effective in reducing alcohol consumption in men drinking more than 60 g and women drinking more than 40 g a day.
Estonian: Inimravimite komitee märkis, et uuringute kohaselt oli Selincro efektiivne alkoholitarbimise vähendamisel meestel, kes tarbisid ööpäevas üle 60 g alkoholi, ja naistel, kes tarbisid ööpäevas üle 40 g alkoholi.
English: Selincro is used to help reduce alcohol consumption in adults with alcohol dependence who consume more than 60 g of alcohol per day (for men) or more than 40 g per day (for women).
Estonian: Selincrot kasutatakse alkoholitarbimise vähendamiseks alkoholisõltuvusega täiskasvanud patsientidel, kes tarbivad ööpäevas enam kui 60 g (mehed) või 40 g (naised) alkoholi.
English: Selincro was compared with placebo (a dummy treatment) in two main studies involving 1,322 men and women with alcohol dependence.
Estonian: Kahes põhiuuringus, milles osales 1322 alkoholisõltuvusega meest ja naist, võrreldi Selincrot platseeboga (näiv ravim).
English: The effects of Selincro were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Selincro toimet muude katsetega.
English: It is available as tablets (18 mg).
Estonian: Selincrot turustatakse 18 mg tablettidena.
English: Selincro was shown to be more effective than placebo in reducing the number of heavy drinking days and daily alcohol consumption.
Estonian: Selincro oli rohke alkoholitarbimise päevade arvu ja keskmise ööpäevas tarbitud alkoholikoguse vähendamisel efektiivsem kui platseebo.
English: Caution is advised if Selincro is prescribed for more than one year.
Estonian: Selincro kasutamisel üle 1 aasta tuleb olla ettevaatlik.
English: How does Selincro work?
Estonian: Kuidas Selincro toimib?
English: What benefit has Selincro shown during the studies?
Estonian: Milles seisneb uuringute põhjal Selincro kasulikkus?
English: Selincro can only be obtained by prescription.
Estonian: Selincro on retseptiravim.
English: How has Selincro been studied?
Estonian: Kuidas Selincrot uuriti?
English: How is Selincro used?
Estonian: Kuidas Selincrot kasutatakse?
English: What is Selincro used for?
Estonian: Milleks Selincrot kasutatakse?
English: The patient should take one Selincro tablet by mouth ‘as needed', which means when there is a risk that they would start drinking.
Estonian: Patsiendid võtavad suukaudselt ühe Selincro tableti vastavalt vajadusele.
English: You may need medical help.
Estonian: Võite vajada meditsiiniabi.
English: Symptoms you should be aware of
Estonian: Sümptomid, millest peate olema teadlik
English: This is because it may harm your unborn baby.
Estonian: Põhjuseks on, et see võib kahjustada teie sündimata last.
English: This means you should:
Estonian: See tähendab, et peate:
English: NA: Not Achieved
Estonian: NA: ei saavutatud
English: Take care in direct sunlight
Estonian: Olge ettevaatlik otsese päikesevalguse käes
English: Patients, n
Estonian: Patsienti, n
English: • It is important to keep taking Rubraca every day - as long as your doctor prescribes it for you.
Estonian: • Tähtis on võtta Rubracat iga päev - kuni arst on seda teile määranud.
English: Treatment was continued until disease progression or unacceptable toxicity.
Estonian: Ravi jätkati kuni haiguse progresseerumiseni või vastuvõetamatu toksilisuseni.
English: • Take the tablets once in the morning and once in the evening, approximately 12 hours apart.
Estonian: • Võtke tablette üks kord hommikul ja teine kord õhtul, ligikaudu 12-tunnise vahega.
English: Date of first authorisation: 24 May 2018 Date of latest renewal: 13 March 2019
Estonian: Müügiloa esmase väljastamise kuupäev: 24. mai 2018 Müügiloa viimase uuendamise kuupäev: 13. märts 2019
English: See section 5.2.
Estonian: Vt lõik 5.2.
English: ARIEL3 Efficacy Results Parameter
Estonian: ARIEL3 efektiivsuse tulemused Parameeter
English: The median progression-free survival was
Estonian: Mediaanne progresseerumisvaba elulemus oli
English: Each carton contains one bottle.
Estonian: Igas karbis on üks pudel.
English: Efficacy results from all patients treated are summarized in Table 5.
Estonian: Kokkuvõte efektiivsusealastest tulemustest kõikidel ravitud patsientidel on kokku võetud tabelis 5.
English: The safety and efficacy of Rubraca in children or adolescents aged less than 18 years have not been established.
Estonian: Rubraca ohutus ja efektiivsus lastel või alla 18-aastastel noorukitel ei ole tõestatud.
English: • You can take the tablets with or without food.
Estonian: • Tablette võib võtta toiduga või ilma toiduta.
English: • The other ingredients are:
Estonian: - Teised koostisosad (abiained) on:
English: • Do not stop taking this medicine without talking to your doctor first.
Estonian: • Ärge lõpetage selle ravimi võtmist arstiga eelnevalt nõu pidamata.
English: The results should be interpreted with caution due to the limited representation of some subgroup phenotypes.
Estonian: Tulemusi tuleb tõlgendada ettevaatusega mõne alamgruppi vähese esindatuse tõttu.
English: • Talk to your doctor or pharmacist about the most effective methods of contraception.
Estonian: • Pidage nõu oma arsti või apteekriga kõige tõhusamate rasestumisvastaste meetodite leidmiseks.
English: Other medicines and Rubraca
Estonian: Muud ravimid ja Rubraca
English: The absolute oral bioavailability at 600 mg has not been determined.
Estonian: Absoluutset suukaudset biosaadavust 600 mg korral ei ole kindlaks määratud.
English: This means you take a total of 1,200 mg each day.
Estonian: See tähendab, et võtate ööpäevas kokku 1200 mg.
English: Median overall survival was not achieved in this population.
Estonian: Sellel rühmal mediaanset üldist elulemust ei saavutatud.
English: HR (95% CI) p-valueb a. All randomised patients.
Estonian: HR (95% CI) p-väärtusb a. Kõik randomiseeritud patsiendid.
English: Contents of the pack and other information What Rubraca contains
Estonian: Pakendi sisu ja muu teave Mida Rubraca sisaldab
English: Efficacy results are summarised in Table 4 and Figure 1.
Estonian: Efektiivsuse tulemused on kokku võetud tabelis 4 ja joonisel 1.
English: The doses should be taken approximately 12 hours apart.
Estonian: Annused tuleb võtta ligikaudu 12-tunnise vahega.
English: Tell your doctor straight away if you notice any of the following side effects - you may need urgent medical treatment:
Estonian: Öelge kohe arstile, kui märkate ükskõik millist järgmist kõrvaltoimet - võite vajada kiiresti ravi:
English: Rucaparib may only be used in patients with severe renal impairment if the potential benefit outweighs the risk.
Estonian: Rukapariibi võib kasutada raske neerukahjustusega patsientidel vaid sel juhul, kui selle potentsiaalne kasulikkus ületab sellega seotud riski.
English: • use a sunscreen and lip balm with a sun protection factor (SPF) of 50 or higher.
Estonian: • kasutama päikesekaitsekreemi ja huulepalsamit kõrge päikesekaitsefaktoriga (SPF) - 50 või kõrgem.
English: Following repeated twice daily dosing, the accumulation based on AUC ranged from 3.5 to 6.2 fold.
Estonian: Pärast korduvat annustamist kaks korda ööpäevas oli akumulatsioon AUC põhjal 3,5- kuni 6,2-kordne.
English: No significant P-gp inhibition was observed in vivo (section 4.5).
Estonian: Olulist P-gp inhibeerimist in vivo ei täheldatud (lõik 4.5).
English: Take care if you feel tired or feel sick (nauseous).
Estonian: Olge ettevaatlik, kui tunnete väsimust või iiveldust.
English: • if you are allergic to rucaparib or any of the other ingredients of this medicine (listed in section 6).
Estonian: • kui olete rukapariibi või selle ravimi mis tahes koostisosade suhtes (loetletud lõigus 6) suhtes allergiline.
English: HRD Groupc
Estonian: HRD gruppc
English: IRR- assessment for the ITT population supported the primary endpoint.
Estonian: IRR hinnang ITT populatsiooni kohta toetas esmast tulemusnäitajat .
English: If you have certain side effects your doctor may recommend a lower dose, or temporarily stop your treatment.
Estonian: Kui teil tekivad teatud kõrvaltoimed, võib teie arst soovitada väiksemat annust või ravi ajutiselt peatada.
English: It is important to proactively manage these events to avoid prolonged or more severe events of nausea/vomiting which have the potential to lead to complications such as dehydration or hospitalisation.
Estonian: Oluline on selliste episoodidega tegeleda ennetavalt vältimaks kauakestvaid või tõsisemaid iivelduse/oksendamise episoode, mis võivad potentsiaalselt põhjustada komplikatsioone, nagu dehüdratsioon või haiglaravi.
English: ITT populationa
Estonian: ITT populatsioona
English: There are limited clinical data in patients aged 75 or over.
Estonian: Kliinilised andmed 75-aastaste või vanemate patsientide kohta on piiratud.
English: Therefore, use in this patient population is not recommended.
Estonian: Seetõttu ei ole selle kasutamine sellel patsiendirühmal soovitatav.
English: Rubraca is supplied in plastic bottles.
Estonian: Rubracat turustatakse plastpudelites.
English: • Women who are able to become pregnant must use effective birth control (contraception):
Estonian: • Rasestumisvõimelised naised peavad kasutama efektiivseid rasestumisvastaseid vahendeid:
English: Platinum Sensitive N=79
Estonian: Plaatinatundlik N=79
English: • Rubraca is not recommended during pregnancy.
Estonian: • Rubracat ei soovitata kasutada raseduse ajal.
English: Your doctor may also do weekly tests, if you have low blood cell counts for a long time.
Estonian: Arst võib teha teile analüüse ka kord nädalas, kui teil on vererakkude arv pikemat aega madalad.
English: Rubraca should not be used during pregnancy unless the clinical condition of the woman requires treatment with rucaparib.
Estonian: Rubracat ei tohi kasutada raseduse ajal, välja arvatud juhul, kui naise kliiniline seisund vajab ravi rukapariibiga.
English: • wear clothing that covers your head, arms and legs
Estonian: • kandma pead, käsi ja jalgu katvaid rõivaid
English: The only serious adverse reaction occurring in > 2% of patients was anaemia (5%).
Estonian: Ainus tõsine kõrvaltoime, mida esines > 2%-l patsientidest, oli aneemia (5%).
English: PFS assessed by blinded independent radiology review (BIR) was a key secondary efficacy outcome.
Estonian: Progressioonivaba elulemus (PFS), mida hindas sõltumatu radioloogia pimemeetodil (blinded independent radiology review, BIR) oli olulise tähtsusega sekundaarse efektiivsuse tulemusnäitaja.
English: This is because Rubraca can affect the way some other medicines work.
Estonian: Põhjuseks on, et Rubraca võib mõjutada mõningate teiste ravimite toimet.